Hemadsorption.
Journal
Current opinion in anaesthesiology
ISSN: 1473-6500
Titre abrégé: Curr Opin Anaesthesiol
Pays: United States
ID NLM: 8813436
Informations de publication
Date de publication:
01 Apr 2021
01 Apr 2021
Historique:
pubmed:
21
1
2021
medline:
6
3
2021
entrez:
20
1
2021
Statut:
ppublish
Résumé
To review pathophysiological pathways of immune system response to infections, which may justify mediators removal by extracorporeal blood purification therapies (EBPTs) in critically ill septic patients. Moreover, we presented an overview of the EBPTs mostly used in clinical practice with the aim to modulate immune system dysfunction in sepsis. Sepsis is a life-threatening disease and recent findings showed that its pathophysiology relies on dysregulated immune system response to pathogen invasion of the body. In the light of this view, EBPTs have been demonstrated effective to remove specific mediators and foster balance between pro- and anti-inflammatory pathways. EBPTs have been widely used in clinical practice, with the aim to modulate immune system dysfunction by the removal of pathogens and inflammatory mediators in critically ill patients with sepsis. Such therapies are characterised by specific structural features, which allow selective and nonselective removal of mediators by adsorption. However, few evidences support their role in the management of critically ill patients with sepsis. Accordingly, an evidence-based and personalized approach to EBPTs in sepsis is strongly advocated, in order to solve controversies in this field and optimise the management of critically ill septic patients.
Identifiants
pubmed: 33470661
doi: 10.1097/ACO.0000000000000953
pii: 00001503-202104000-00009
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
113-118Informations de copyright
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
Références
Rhodes A, Evans L, Alhazzani W, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock: 2016. Intensive Care Med 2017; 43:304–377.
Rhee C, Klompas M. Sepsis trends: increasing incidence and decreasing mortality, or changing denominator? J Thorac Dis 2020; 12: (Suppl 1): S89–S100.
Rudd K, Johnson S, Agesa K, et al. Global, regional, and national sepsis incidence and mortality, 1990-2017: analysis for the Global Burden of Disease Study. Lancet 2020; 395:200–211.
Cutuli S, De Pascale G, Antonelli M. ‘σeeacgrψιζ’ yesterday, sepsis nowadays: what's changing? J Thorac Dis 2017; 9:E166–E167.
Laffey J, Kavanagh B. Negative trials in critical care: why most research is probably wrong. Lancet Respir Med 2018; 6:659–660.
Helms J, Perner A. Focus on sepsis. Intensive Care Med 2020; 46:1457–1459.
Singer M, Deutschman C, Seymour C, et al. The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA 2016; 315:801–810.
Cutuli S, Carelli S, De Pascale G. The gut in critically ill patients: how unrecognized ‘7th organ dysfunction’ feeds sepsis. Minerva Anestesiol 2020; 86:595–597.
Hotchkiss R, Moldawer L, Opal S, et al. Sepsis and septic shock. Nat Rev Dis Primers 2016; 2:1–47.
Vincent J, Moreno R, Takala J, et al. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med 1996; 22:707–710.
Ronco C, Clark W. Haemodialysis membranes. Nat Rev Nephrol 2018; 14:394–410.
Douvris A, Malhi G, Hiremath S, et al. Interventions to prevent hemodynamic instability during renal replacement therapy in critically ill patients: a systematic review. Crit Care 2018; 22:1–11.
Young P, Saxena M, Beasley R, et al. Early peak temperature and mortality in critically ill patients with or without infection. Intensive Care Med 2012; 38:437–444.
Kushimoto S, Gando S, Saitoh D, et al. The impact of body temperature abnormalities on the disease severity and outcome in patients with severe sepsis: an analysis from a multicenter, prospective survey of severe sepsis. Crit Care 2013; 17:1–9.
Cutuli S, See E, Osawa E, et al. Accuracy of noninvasive body temperature measurement methods in adult patients admitted to the Intensive Care Unit: a systematic review and meta-analysis. Crit Care Resusc. In press.
Guéry B, Alberti C, Servais A, et al. Hemodialysis without systemic anticoagulation: a prospective randomized trial to evaluate 3 strategies in patients at risk of bleeding. PLoS One 2014; 9:e97187.
Yumoto M, Nishida O, Moriyama K, et al. In vitro evaluation of high mobility group box 1 protein removal with various membranes for continuous hemofiltration. Ther Apher Dial 2011; 15:385–393.
Inagaki O, Nishian Y, Iwaki R, et al. Adsorption of nafamostat mesilate by hemodialysis membranes. Artif Organs 1992; 16:553–558.
Malard B, Lambert C, Kellum J. In vitro comparison of the adsorption of inflammatory mediators by blood purification devices. Intensive Care Med Exp 2018; 6:1–13.
Broman M, Hansson F, Vincent J, Bodelsson M. Endotoxin and cytokine reducing properties of the oXiris membrane in patients with septic shock: A randomized crossover double-blind study. PLoS One 2019; 14:1–14.
Villa G, Romagnoli S, De Rosa S, et al. Blood purification therapy with a hemodiafilter featuring enhanced adsorptive properties for cytokine removal in patients presenting COVID-19: a pilot study. Crit Care 2020; 24:1–13.
Cascarano L, Cutuli SL, Pintaudi G, et al. Extracorporeal immune modulation in COVID-19 induced immune dysfunction and secondary infections: the role of oXiris membrane. Minerva Anestesiol 2020.
Mariano F, Leporati M, Carignano P, et al. Efficient removal of colistin A and B in critically ill patients undergoing CVVHDF and sorbent technologies. J Nephrol 2015; 28:623–631.
Livigni S, Bertolini G, Rossi C, et al. Efficacy of coupled plasma filtration adsorption (CPFA) in patients with septic shock: a multicenter randomised controlled clinical trial. BMJ Open 2014; 4:e003536.
Gemelli C, Cuoghi A, Magnani S, et al. Removal of bilirubin with a new adsorbent system: in vitro kinetics. Blood Purif 2019; 47:10–15.
Hassan K, Kannmacher J, Wohlmuth P, et al. Cytosorb adsorption during emergency cardiac operations in patients at high risk of bleeding. Ann Thorac Surg 2019; 108:45–51.
Schädler D, Pausch C, Heise D, et al. The effect of a novel extracorporeal cytokine hemoadsorption device on IL-6 elimination in septic patients: a randomized controlled trial. PLoS One 2017; 12:
Ronco C, Klein D. Polymyxin B hemoperfusion: a mechanistic perspective. Crit Care 2014; 18:1–7.
Shimokawa K, Takakuwa R, Wada Y, et al. Adsorption of various antimicrobial agents to endotoxin removal polymyxin-B immobilized fiber (Toraymyxin®). Part 2: Adsorption of two drugs to Toraymyxin PMX-20R cartridges. Colloids Surf B Biointerfaces 2013; 101:350–352.
Cruz D, Antonelli M, Fumagalli R, et al. Early use of polymyxin B hemoperfusion in abdominal septic shock: the EUPHAS randomized controlled trial. JAMA 2009; 301:2445–2452.
The EUPHAS2 Collaborative Group. Polymyxin B hemoperfusion in clinical practice: the picture from an unbound collaborative registry. Blood Purif 2014; 37: (Suppl 1): 22–25.
Cutuli S, Artigas A, Fumagalli R, et al. Polymyxin-B hemoperfusion in septic patients: analysis of a multicenter registry. Ann Intensive Care 2016; 6:1–9.
Payen D, Guilhot J, Launey Y, et al. Early use of polymyxin B hemoperfusion in patients with septic shock due to peritonitis: a multicenter randomized control trial. Intensive Care Med 2015; 41:975–984.
Dellinger R, Bagshaw S, Antonelli M, et al. Effect of targeted polymyxin B hemoperfusion on 28-day mortality in patients with septic shock and elevated endotoxin level: The EUPHRATES Randomized Clinical Trial. JAMA 2018; 320:1455–1463.
Fujii T, Ganeko R, Kataoka Y, et al. Polymyxin B-immobilized hemoperfusion and mortality in critically ill adult patients with sepsis/septic shock: a systematic review with meta-analysis and trial sequential analysis. Intensive Care Med 2018; 44:167–178.
Chang T, Tu Y, Lee C, et al. Effects of polymyxin B hemoperfusion on mortality in patients with severe sepsis and septic shock: a systemic review, meta-analysis update, and disease severity subgroup meta-analysis. Crit Care Med 2017; 45: ìe858-e64.
Klein D, Foster D, Walker P, et al. Polymyxin B hemoperfusion in endotoxemic septic shock patients without extreme endotoxemia: a post hoc analysis of the EUPHRATES trial. Intensive Care Med 2018; 44:2205–2212.
Romaschin A, Obiezu-Forster C, Shoji H, Klein D. Novel insights into the direct removal of endotoxin by polymyxin B hemoperfusion. Blood Purif 2017; 44:193–197.
Srisawat N, Tungsanga S, Lumlertgul N, et al. The effect of polymyxin B hemoperfusion on modulation of human leukocyte antigen DR in severe sepsis patients. Crit Care 2018; 22:1–10.
Seffer M, Cottam D, Forni L, Kielstein J. Heparin 2.0: a new approach to the infection crisis. Blood Purif 2020; Online ahead of print:1-7.
Schmidt J, Eden G, Seffer M, et al. In vitro elimination of antiinfective drugs by the Seraph ® 100 Microbind ® affinity blood filter. Clin Kidney J 2020; 13:421–424.
Harm S, Schildböck C, Hartmann J. Cytokine removal in extracorporeal blood purification: an in vitro study. Blood Purif 2020; 49:33–43.
Hiraiwa T, Moriyama K, Matsumoto K, et al. In vitro evaluation of linezolid and doripenem clearance with different hemofilters. Blood Purif 2020; 49:295–301.